Titanovo Logo
Back to Cell Types

Granta-519Homo sapiens (Human)Cancer cell line

Also known as: G519, G-519, GRANTA519, Granta519, Granta 519, GRANTA-519

🤖 AI SummaryBased on 13 publications

Quick Overview

Granta-519 is a human mantle cell lymphoma cell line used in cancer research.

Detailed Summary

Granta-519 is a human mantle cell lymphoma (MCL) cell line derived from a patient with mantle cell lymphoma. It is widely used in research to study the molecular mechanisms of MCL and to evaluate potential therapeutic strategies. This cell line is known for its expression of cyclin D1 due to the t(11;14) chromosomal translocation, which is a hallmark of MCL. Granta-519 has been utilized in studies investigating the effects of various drugs, including BCL-2 inhibitors and other targeted therapies, to understand their efficacy and mechanisms of action in MCL. The cell line is also used to explore the role of specific genetic mutations and signaling pathways in the progression and treatment resistance of MCL.

Research Applications

Mantle cell lymphoma researchDrug sensitivity testingMolecular mechanism studiesTherapeutic target identification

Key Characteristics

Expresses cyclin D1 due to t(11;14) translocationUsed in studies of BCL-2 inhibitorsUtilized for investigating treatment resistance mechanisms
Generated on 6/17/2025

Basic Information

Database IDCVCL_1818
SpeciesHomo sapiens (Human)
Tissue SourcePeripheral blood[UBERON:UBERON_0000178]

Donor Information

Age58
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseMantle cell lymphoma
LineageLymphoid
SubtypeMantle Cell Lymphoma
OncoTree CodeMCL

DepMap Information

Source TypeDSMZ
Source IDACH-000073_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
Gene deletionCDKN2A-HomozygousPossiblePubMed=26870271

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
9,11
D16S539
11,12
D18S51
17,18
D19S433
12,13
D21S11
28,30
D2S1338
16,17
D3S1358
15,16
D5S818
9,13
D7S820
10,14
D8S1179
14,15
FGA
22,24
Penta D
9
Penta E
7,12
TH01
7,8
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.

Clin. Cancer Res. 24:3967-3980(2018).

DOIPubMed

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Isik E., Letai A.G., Lossos I.S.

Blood 126:1555-1564(2015).

DOIPubMedPMC

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.

Cytometry A 87:285-288(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

J. Virol. 89:713-729(2015).

DOIPubMedPMC

Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma.

Lenz G., Stegmeier F.

Nat. Med. 20:87-92(2014).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.

Martinez-Climent J.A.

Proc. Natl. Acad. Sci. U.S.A. 108:12461-12466(2011).

DOIPubMedPMC

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis.

Jares P.

Blood 109:5422-5429(2007).

DOIPubMed

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Martinez-Climent J.A.

Blood 109:271-280(2007).

DOIPubMed

Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines.

Colomer D., Miro R., Campo E.

Leuk. Res. 30:923-934(2006).

DOIPubMed

Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519.

Schlegelberger B.

Cancer Genet. Cytogenet. 153:144-150(2004).

DOIPubMed

Characterization of 4 mantle cell lymphoma cell lines. Establishment of an in vitro study model.

Leventaki V., O'Connor S.L., Keating M.J., Lai R.

Arch. Pathol. Lab. Med. 127:424-431(2003).

DOIPubMed

Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Elenitoba-Johnson K.S.J.

J. Mol. Diagn. 4:123-136(2002).

DOIPubMedPMC

Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519).

Catovsky D.

Leukemia 11:64-72(1997).

DOIPubMed

BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation.

Strauss M., Bartek J.

Oncogene 9:2159-2167(1994).

PubMed

Deletions and rearrangement of CDKN2 in lymphoid malignancy.";

Millar J.L., Catovsky D., Dyer M.J.S.

Blood 85:893-901(1995).

DOIPubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

thermofisher.comtcpaportal.org